{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T11:27:22Z","timestamp":1749900442874,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":314,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Identifying the druggable target is crucial for patients with nonsquamous advanced non-small cell lung cancer (NSCLC). This article adds to the spectrum of ROS1 fusion cases described in NSCLC. We describe a novel SLC12A2-ROS1 rearrangement that has not been previously reported in other cancers: a fusion that has clinical and radiological sensitivity to crizotinib. Fluorescence in situ hybridization detected the SLC12A2-ROS1 fusion and it was confirmed through hybrid capture-based next-generation sequencing (NGS); however, the fusion could not be detected by amplicon-based assay. The success of implementing NGS into routine clinical practice depends on the accuracy of testing. The test's methodological features should then be considered because they significantly affect the results. Given this patient's response to crizotinib, identifying patients with undescribed ROS1 fusions has important therapeutic implications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>This is the first known description of an SLC12A2-ROS1 fusion. Considering the patient's clinical features and tumor response observed after crizotinib therapy, the authors confirm that this new rearrangement has relevant clinical impact for patients with non-small cell lung cancer. The success of implementing next-generation sequencing (NGS) into routine clinical practice depends on the accuracy of the testing. Different assays and NGS platforms can achieve differing results. Each assay's limitations need to be considered to ensure the quality of precision medicine in clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13745","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T12:52:05Z","timestamp":1615207925000},"page":"e908-e912","source":"Crossref","is-referenced-by-count":7,"title":["Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-0771","authenticated-orcid":false,"given":"Carlos","family":"Rodr\u00edguez-Antol\u00edn","sequence":"first","affiliation":[{"name":"Epigenetics Laboratory, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-2161","authenticated-orcid":false,"given":"Roc\u00edo","family":"Rosas-Alonso","sequence":"additional","affiliation":[{"name":"Epigenetics Laboratory, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Cruz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Higuera","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo","family":"S\u00e1nchez-Cabrero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Esteban-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Department of Pathology, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Pel\u00e1ez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Molecular Pathology and Therapeutic Targets, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Eugenia","family":"Fern\u00e1ndez Monta\u00f1o","sequence":"additional","affiliation":[{"name":"Structural and Functional Genomics, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Rodr\u00edguez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Genetics of Metabolic Diseases, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Ib\u00e1\u00f1ez de C\u00e1ceres","sequence":"additional","affiliation":[{"name":"Epigenetics Laboratory, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Castro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"2022020821443599700_onco13745-bib-0001","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"2022020821443599700_onco13745-bib-0002","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"2022020821443599700_onco13745-bib-0003","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000398","article-title":"Multidisciplinary molecular tumour board: A tool to improve clinical practice and selection accrual for clinical trials in patients with cancer","volume":"3","author":"Rolfo","year":"2018","journal-title":"ESMO Open"},{"key":"2022020821443599700_onco13745-bib-0004","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2022020821443599700_onco13745-bib-0005","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3727\/096504019X15509372008132","article-title":"Different types of ROS1 fusion partners yield comparable efficacy to crizotinib","volume":"27","author":"He","year":"2019","journal-title":"Oncol Res"},{"key":"2022020821443599700_onco13745-bib-0006","first-page":"156","article-title":"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer","volume":"4","author":"Kohno","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"2022020821443599700_onco13745-bib-0007","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"2022020821443599700_onco13745-bib-0008","first-page":"100048","article-title":"A catalog of 5\u2019 fusion partners in ROS1-positive NSCLC circa 2020","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"2022020821443599700_onco13745-bib-0009","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022020821443599700_onco13745-bib-0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc3947","article-title":"The emerging complexity of gene fusions in cancer","volume":"15","author":"Mertens","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2022020821443599700_onco13745-bib-0011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/diagnostics10080521","article-title":"Next generation sequencing for gene fusion analysis in lung cancer: A literature review","volume":"10","author":"Bruno","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2022020821443599700_onco13745-bib-0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: A joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"2022020821443599700_onco13745-bib-0013","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022020821443599700_onco13745-bib-0014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/gcc.22819","article-title":"Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays","volume":"59","author":"Pfarr","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"2022020821443599700_onco13745-bib-0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cancergen.2020.02.007","article-title":"Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by Illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN","volume":"243","author":"Qu","year":"2020","journal-title":"Cancer Genet"},{"key":"2022020821443599700_onco13745-bib-0016","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK fusions: Merits and limitations of current diagnostic platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res"},{"key":"2022020821443599700_onco13745-bib-0017","first-page":"1","article-title":"Operationalization of next-generation sequencing and decision support for precision oncology","volume":"3","author":"Zeng","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"2022020821443599700_onco13745-bib-0018","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jtho.2018.04.016","article-title":"Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non-small cell lung cancer","volume":"13","author":"Li","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2022020821443599700_onco13745-bib-0019","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13745","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13745","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e908\/42375570\/oncolo_26_6_e908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e908\/42375570\/oncolo_26_6_e908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T21:53:10Z","timestamp":1644357190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/6\/e908\/6520943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,26]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13745","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,3,26]]}}}